US wants more info on female libido pill

February 11, 2014 by Matthew Perrone

A drugmaker working to develop a pill to boost sexual desire in women says regulators are demanding more studies on the experimental drug.

Sprout Pharmaceuticals said Tuesday that the Food and Drug Administration wants to see more data on how the company's drug, flibanserin, interacts with other medications and how it affects driving ability. Nearly 10 percent of women studied in company trials reported sleepiness while taking the daily pill.

The FDA's request represents another hurdle in the 's 15-year search for a female equivalent to Viagra.

But in a news release, Sprout Pharmaceuticals President Cindy Whitehead described the development as a "significant step toward the approval of flibanserin." The three studies requested by the FDA are relatively small, involving 25 to 50 patients each. The company says it plans to resubmit its to FDA in the third quarter.

The company based in Raleigh, North Carolina, said in December that it had reached an "impasse" with regulators after the agency issued a second rejection letter on the drug. The company filed a formal dispute over the agency's decision, which prompted the FDA's latest request for additional studies.

If approved, Sprout's daily pill would be the first drug for women who report a lack of , a market that drugmakers have been trying to tap since the blockbuster success of Viagra for men in the late 1990s. While earlier drugs worked on hormone levels, flibanserin is the first attempt to increase sexual desire by acting on brain chemicals that affect appetite and mood.

The race to develop a female libido booster was once dominated by multinational companies like Viagra-maker Pfizer Inc. and Procter & Gamble, but today the space mainly consists of tiny startups. Sprout Pharmaceuticals, led by a husband and wife team, acquired flibanserin from Boehringer Ingelheim in 2011, after the German conglomerate abandoned development following an FDA rejection letter. Boehringer studies showed that women taking the drug reported only a modest uptick in "sexually satisfying events."

The FDA's initial rejection followed a 2010 meeting where a panel of expert advisers unanimously voted against the drug, citing its lackluster effectiveness and side effects such as fatigue, dizziness and nausea.

Even if the FDA eventually approves flibanserin, Sprout will have to convince doctors to prescribe the drug for a condition that is still viewed with some skepticism.

The would be specifically approved for premenopausal women with hypoactive sexual desire disorder, described as a lack of sexual appetite that causes emotional distress. Because so many factors affect female sexual appetite, there are a number of other possible causes doctors must rule out before diagnosing the condition, including relationship problems, hormone disorders, depression and mood issues caused by other drugs like sleeping aids and pain medications.

Explore further: Female libido drug remains in limbo (Update)

Related Stories

Female libido drug remains in limbo (Update)

December 11, 2013

The 15-year search for a pill that boosts sexual desire in women has hit another roadblock, raising questions about the future of efforts to develop a female equivalent to Viagra.

Not in the mood but want to be? New studies bring women hope

December 4, 2013

For women, passing midlife can deal a blow to their sex drive. But two new studies just published online in Menopause, the journal of The North American Menopause Society, offer hope to women who want to get their sexual ...

Recommended for you

Researchers identify source of opioids' side effects

January 17, 2017

A commercially available drug may help drastically reduce two side effects of opioid painkillers—a growing tolerance and a paradoxical increased sensitivity to pain—without affecting the drugs' ability to reduce pain, ...

CVS generic competitor to EpiPen, sold at a 6th the price

January 12, 2017

CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to ...

Many misuse OTC sleep aids: survey

December 29, 2016

(HealthDay)—People struggling with insomnia often turn to non-prescription sleep remedies that may be habit-forming and are only intended for short-term use, according to a new Consumer Reports survey.

The pill won't kill your sexual desire, researchers say

December 15, 2016

Taking the pill doesn't lower your sexual desire, contrary to popular belief, according to research published in the Journal of Sexual Medicine. The authors of the research, from the University of Kentucky and Indiana University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.